Insulet is trading 4.15% down at $148.43 in pre-market on November 4 following its earnings release; available sources do not establish a specific cause for the decline.
- Third-quarter revenue was $842.0 million and adjusted earnings were $1.99 per share, both above analyst expectations.
- Insulet raised its full-year revenue and margin outlook and authorized a $1 billion share repurchase program.
- The healthcare sector and major U.S. indices were higher pre-market, so broad-market weakness does not explain the move.